Health care associated infections, antibiotic resistance and clinical outcome: A surveillance study from Sanandaj, Iran

Table 3 Antibiotic susceptibility patterns of gram-negative bacteria isolated from sanandaj hospitals, Iran, 2012 (% susceptible)

	Escherichia coli	Klebsiella pneumoniae	Klebsiella oxytoca	Serratia marcescens	Serratia ordorifera	Acinetobacter	Species enterobacter	Pseudomonas aeruginosa	Pseudomonas orizihibitans	Pseudomonas luteola	Stenotropho-monas	Suscepti bility of all Isolates	No. ofisolates tested
Ampicillin	1 (6.7)	3 (20)	0 (0)	1 (3.3)	0 (0)	0 (0)	0 (0)	-	-	-	-	5 (6.7)	74
Amoxicillin	2 (13.3)	1 (6.7)	0 (0)	1 (3.3)	0 (0)	0 (0)	1 (20)	-	-	-	-	5 (6.7)	74
Amikacin	14 (93.3)	8 (53.3)	1 (100)	23 (76.7)	2 (66.7)	2 (40)	4 (80)	2 (100)	1 (100)	1 (100)	1 (100)	58 (73.4)	79
Gentamicin	11 (73.3)	7 (46.7)	0 (0)	22 (73.3)	1 (33.3)	0 (0)	4 (80)	2 (100)	1 (100)	1 (100)	0 (0)	48 (60.7)	79
Tobramycin	-	-	-	-	-	-	-	2 (100)	1 (100)	1 (100)	0 (0)	4 (80)	5
Cotrimoxazole	2 (13.3)	6 (40)	0 (0)	21 (70)	2 (66.7)	1 (20)	4 (80)	0 (0)	0 (0)	0 (0)	0 (0)	36 (45.5)	79
Nitrofurantoin	15 (100)	10 (66.7)	0 (0)	6 (20)	2 (66.7)	0 (0)	3 (60)	-	-	-	-	35 (47.2)	74
Cephalothin	6 (40)	5 (33.3)	0 (0)	1 (3.3)	1 (33.3)	0 (0)	1 (20)	-	-	-	-	13 (17.6)	74
Cefixime	10 (66.7)	5 (33.3)	0 (0)	22 (73.3)	1 (33.3)	0 (0)	2 (40)	-	-	-	-	39 (52.7)	74
Cefotaxime	9 (60)	5 (33.3)	0 (0)	22 (73.3)	1 (33.3)	0 (0)	4 (80)	-	-	-	-	40 (54)	74
Ceftazidim	11 (73.3)	5 (33.3)	0 (0)	24 (80)	2 (66.7)	0 (0)	4 (80)	2 (100)	1 (100)	1 (100)	0 (0)	49 (62)	79
Ceftriaxone	8 (53.3)	6 (40)	0 (0)	22 (73.3)	1 (33.3)	0 (0)	3 (60)	-	-	-	-	39 (52.7)	74
Cefepim	13 (86.7)	7 (46.7)	0 (0)	24 (80)	3 (100)	0 (0)	4 (80)	1 (50)	1 (100)	1 (100)	0 (0)	52 (65.8)	79
Ciprofloxacin	11 (73.3)	13 (86.7)	0 (0)	30 (100)	3 (100)	1 (20)	4 (80)	2 (100)	1 (100)	1 (100)	0 (0)	65 (82.3)	79
Levofloxacin	11 (73.3)	13 (86.7)	0 (0)	30 (100)	3 (100)	1 (20)	5 (100)	2 (100)	1 (100)	1 (100)	1 (100)	67 (84.8)	79
Imipenem	15 (100)	15 (100)	1 (100)	30 (100)	3 (100)	5 (100)	5 (100)	2 (100)	1 (100)	1 (100)	1 (100)	79 (100)	79
Meropenem	-	-	-	-	-	-	-	2 (100)	1 (100)	1 (100)	1 (100)	5 (100)	5
Carbenicillin	-	-	-	-	-	-	-	2 (100)	1 (100)	1 (100)	0 (0)	4 (80)	5
Ticarcillin	-	-	-	-	-	-	-	2 (100)	1 (100)	1 (100)	0 (0)	4 (80)	5
Piperacillin	-	-	-	-	-	-	-	2 (100)	1 (100)	1 (100)	0 (0)	4 (80)	5
Piperacillin/ Tazobactam	10 (66.7)	13 (86.7)	1 (100)	27 (90)	3 (100)	0 (0)	4 (80)	2 (100)	1 (100)	1 (100)	-	57 (73)	78
Aztreonam	-	-	-	-	-	-	-	2 (100)	1 (100)	1 (100)	-	3 (75)	4
ESBL(positive)	5 (33.3)1	10 (66.7)1	-	-	-	-	-	-	-	-	-	16 (51.6)1	311
Total susceptible isolates (%)	149 (62.1)	122 (50.8)	3 (18.7)	306 (63.7)	28 (58.3)	10 (12.5)	52 (65)	27 (90)	14 (93.3)	14 (93.3)	4 (30.7)	711 (56.6)2	--
Total isolates tested (sum)	240	240	16	480	48	80	80	30	15	15	13	--	1257

¹Not counted in the sum and susceptibility percents;

²Total sensitive Isolates (% susceptibility of total tested isolates).